4 results
1. The primary objective of this phase I/II clinical trial is to evaluate the safety and toxicity of ACT plus nivolumab according to CTCAE 4.0 criteria. Toxicity grade 3 or less and SAE related to treatment but that does not result in treatment…
To provide continued bevacizumab therapy as single agent or in combination with an anti-cancer drug to patients with cancer, who were previously enrolled in a F. Hoffmann-La Roche (Roche)/ Genentech sponsored bevacizumab study (i.e. the Parent, P-…
To confirm the safety of the Articulinx implant by evaluating device and procedure related adverse events.
The primary objective of this trial is to compare the number of postoperative wound complications in patients with and without negative pressure therapy after breast conserving surgery in the first three months after surgery. Wound complications…